Low-risk MDS: Oral azacitidine provides meaningful reduction in RBC transfusion burden April 2, 2021Myelodysplastic Syndrome
Hematology NewsOmidubicel improves on umbilical cord blood transplantsMarch 22, 2021TransplantALLAMLCMLMyelodysplastic SyndromeB Cell LymphomaLeukemia, Myelodysplasia, Transplantation
Fibrinogen-albumin ratio index prognostic for OS in MDS patients treated with azacitidineMarch 8, 2021Myelodysplastic Syndrome
MDS: Comparative response of reduced-dose decitabine and azacitidineMarch 8, 2021Myelodysplastic Syndrome
Daratumumab shows limited benefit in transfusion-dependent patients with low- to intermediate-risk MDS March 8, 2021Myelodysplastic Syndrome
Baseline and serial molecular profiling can predict outcomes with HMAs in MDSMarch 8, 2021Myelodysplastic Syndrome
High erythroferrone expression in CD71+ erythroid progenitors predicts superior survival in MDSMarch 8, 2021Myelodysplastic Syndrome
Impact of conditioning intensity and genomics on relapse after allogeneic HCT in MDSMarch 8, 2021Myelodysplastic Syndrome
Eprenetapopt and azacitidine combination yields high response rates in TP53-mutant MDSMarch 8, 2021Myelodysplastic Syndrome
Hematology NewsUsing engineered T cells reduced acute, chronic GVHDFebruary 23, 2021TransplantALLAMLB Cell LymphomaMyelodysplastic SyndromeLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
Hematology NewsChronic GVHD therapies offer hope for treating refractory diseaseFebruary 17, 2021TransplantLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMyelodysplastic SyndromeMultiple MyelomaALLAML
Monitoring treatment with 5-azacitidine by flow cytometry predicts duration of hematological response in MDSFebruary 1, 2021Myelodysplastic Syndrome
